Galena Biopharma Shares Outstanding 2008-2021 | SLS

Galena Biopharma shares outstanding from 2008 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Galena Biopharma Annual Shares Outstanding
(Millions of Shares)
2020 8
2019 3
2018 0
2017 0
2016 0
2015 0
2014 0
2013 0
2012 0
2011 0
2010 0
2009 0
2008 0
2007 0
Galena Biopharma Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 15
2021-03-31 15
2020-12-31 8
2020-09-30 8
2020-06-30 7
2020-03-31 6
2019-12-31 3
2019-09-30 4
2019-06-30 1
2019-03-31 0
2018-12-31 0
2018-09-30 0
2018-06-30 0
2018-03-31 0
2017-12-31 0
2017-09-30 0
2017-06-30 0
2017-03-31 0
2016-12-31 0
2016-09-30 0
2016-06-30 0
2016-03-31 0
2015-12-31 0
2015-09-30 0
2015-06-30 0
2015-03-31 0
2014-12-31 0
2014-09-30 0
2014-06-30 0
2014-03-31 0
2013-12-31 0
2013-09-30 0
2013-06-30 0
2013-03-31 0
2012-12-31 0
2012-09-30 0
2012-06-30 0
2012-03-31 0
2011-12-31 0
2011-09-30 0
2011-06-30 0
2011-03-31 0
2010-12-31 0
2010-09-30 0
2010-06-30 0
2010-03-31 0
2009-12-31 0
2009-09-30 0
2009-06-30 0
2009-03-31 0
2008-12-31 0
2008-09-30 0
2008-06-30 0
2008-03-31 0
2007-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.159B $0.002B
SELLAS Life Sciences Group is a development-stage biopharmaceutical company. It focused on novel cancer immunotherapeutics for cancer indications. The company's product candidate, galinpepimut-S, is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 protein, which is present in an array of tumor types. SELLAS Life Sciences Group Inc., formerly known as Galena Biopharma Inc., is based in NEW YORK, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29